跳至主要内容
临床试验/NCT03825302
NCT03825302撤回不适用

Prostaglandin E2 as a Critical Mediator of Sex Disparities in Asthma

Vanderbilt University Medical Center1 个研究点 分布在 1 个国家开始时间: 2021年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
Provacative dose of mannitol that elicits a 15% decline in forced expiratory volume in males

研究概览

简要总结

This study seeks to understand how biological sex influences airway hyperresponsiveness in adult asthma.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subject must be able to understand and provide informed consent
  • Age 18-50
  • A history of physician-diagnosed asthma well controlled as assessed by ACQ-6 <1.5 and FEV1>70% of predicted and FEV1 >1.5 liters.
  • Asthma must be persistent, defined by the requirement of a daily controller agent.
  • Use of a stable dose of daily inhaled corticosteroids for the prior 3 months.
  • Female subjects of childbearing potential must have a negative pregnancy test upon study entry and at each study visit.

排除标准

  • Inability or unwillingness of a participant to give written informed consent or comply with study protocol.
  • Hypogonadism, irregular menstrual cycles, polycystic ovarian syndrome (PCOS), exogenous hormonal supplements or contraception.
  • Any chronic lung condition outside of asthma including chronic obstructive pulmonary disease (COPD), interstitial lung disease, eosinophilic granulomatosis with polyangiitis, allergic bronchopulmonary aspergillosis.
  • Inability or unwillingness to hold the following medications prior to mannitol and methacholine inhalational challenge(s): Short-Acting Beta 2 Agonists >8 hours, Inhaled Corticosteroids and Anticholinergic Bronchodilators >12 hours, Phosphodiesterase Inhibitors or Adenosine Receptors >24 hours, Long-acting Beta 2 Agonists >36 hours, Long-acting Anticholinergics or Short-Acting Antihistamines >48 hours, Long-Acting Antihistamines >72 hours, and Leukotriene-Receptor Antagonist or 5-Lipooxygenase Inhibitors >4 days.
  • For males, a screening morning serum total testosterone level (obtained between 8-10 AM) below the normal reference lab value.
  • Current pregnancy, breast-feeding, or plans to become pregnant during the study period.
  • Oral or systemic corticosteroid use or biologic agent for asthma in the previous 3 months or ED/Hospitalization for asthma within 6 months.
  • Use of investigational drugs within 12 weeks of participation.
  • Known hypersensitivity or allergy to mannitol, gelatin or methacholine.
  • Upper or lower respiratory tract infection within the proceeding 6 weeks.
  • A history of uncontrolled hypertension, coronary artery disease, stroke, epilepsy, urinary tract obstruction, untreated thyroid disease, or a chronic lung disease other than asthma.
  • Daily use of a beta-blocker.
  • Intolerance to anticholinergic medications.
  • Inability to produce an adequate sputum sample.
  • Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

结局指标

主要结局

Provacative dose of mannitol that elicits a 15% decline in forced expiratory volume in males

时间窗: Baseline

Males only

Provacative dose of mannitol that elicits a 15% decline in forced expiratory volume in females

时间窗: Baseline

Females only during the luteal phase of the menstrual cycle

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Katherine Cahill

Assistant Professor

Vanderbilt University Medical Center

研究点 (1)

Loading locations...

相似试验